FrancophonIA/ELRC3.0 huggingface dataset:
English: Ferrets in areas endemic for heartworm, or those which have travelled to endemic areas, may be infected with adult heartworms.
Estonian: Tuhkrud, kes elavad ohustatud piirkonnas, või kes sinna piirkonda reisivad, võivad nakatuda südameusstõppe.
English: Loose debris should be gently removed from the external ear canal at each treatment.
Estonian: Enne iga ravi puhastada kuulmekäik nahaosistest.
English: Roundworm and hookworm treatment (Toxocara cati and Ancylostoma tubaeforme).
Estonian: Ümarusside ja kidausside nakkuse ravi (Toxocara cati ja Ancylostoma tubaeforme):
English: For cats, the corresponding “Advocate for cat” product, which contains 100 mg/ml imidacloprid and 10 mg/ml moxidectin, must be used.
Estonian: Kassidel kasutada kassidele mõeldud preparaati “Advocate kassidele”, mis sisaldab 100mg/ml imidaklopriidi ja 10 mg/ml moksidektiini.
English: Up to 10 times the recommended dose was tolerated in adult dogs with no evidence of adverse effects or undesirable clinical signs.
Estonian: Kuni 10 kordseid üledoose talusid koerad hästi ilma kõrvaltoimete ilmnemiseta.
English: Louse
Estonian: Solge
English: Bayer Animal Health GmbH 51368 Leverkusen GERMANY
Estonian: Bayer Animal Health GmbH 51368 Leverkusen Saksamaa
English: • the prevention of heartworm disease (L3 and L4 larvae of Dirofilaria immitis).
Estonian: • südameusstõve (Dirofilaria immitis`e L3 ja L4 vastsed) vältimiseks.
English: for cats
Estonian: Partii {number} Kass
English: EU/2/03/039/011 3 pipettes EU/2/03/039/012 6 pipettes EU/2/03/039/018 4 pipettes EU/2/03/039/029 21 pipettes EU/2/03/039/030 42 pipettes EU/2/03/039/051 1 pipette EU/2/03/039/052 2 pipettes EU/2/03/039/053 9 pipettes EU/2/03/039/054 12 pipettes
Estonian: EU/2/03/039/011 3 pipetti EU/2/03/039/012 6 pipetti EU/2/03/039/018 4 pipetti EU/2/03/039/029 21 pipetti EU/2/03/039/030 42 pipetti EU/2/03/039/051 1 pipett EU/2/03/039/052 2 pipetti EU/2/03/039/053 9 pipetti EU/2/03/039/054 12 pipetti
English: • the treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of Toxocara cati and Ancylostoma tubaeforme).
Estonian: • seedekulgla ümarusside (L4 vastsed, Toxocara cati ja Ancylostoma tubaeforme täiskasvanud ja noorvormid) nakkuse raviks.
English: In areas endemic for heartworm, monthly treatment may significantly reduce the risk of re-infection caused by the respective roundworm, hookworms and whipworms.
Estonian: Südameussidega ohustatud piirkonnas vähendab igakuine ravi märkimisväärselt ümarussidega taasnakatumisriski.
English: Salivation may occasionally occur if the animal licks the application site immediately after treatment.
Estonian: Kui loom vahetult pärast ravimi manustamist lakub manustamiskohta, võib tekkida salivatsioon.
English: EU/2/03/039/009 3 pipettes EU/2/03/039/010 6 pipettes EU/2/03/039/017 4 pipettes EU/2/03/039/027 21 pipettes EU/2/03/039/028 42 pipettes EU/2/03/039/047 1 pipette EU/2/03/039/048 2 pipettes EU/2/03/039/049 9 pipettes EU/2/03/039/050 12 pipettes
Estonian: EU/2/03/039/009 3 pipetti EU/2/03/039/010 6 pipetti EU/2/03/039/017 4 pipetti EU/2/03/039/027 21 pipetti EU/2/03/039/028 42 pipetti EU/2/03/039/047 1 pipett EU/2/03/039/048 2 pipetti EU/2/03/039/049 9 pipetti EU/2/03/039/050 12 pipetti
English: • the treatment and prevention of flea infestation (Ctenocephalides felis),
Estonian: • kirbunakkuse (Ctenocephalides felis) tõrjeks ja raviks,
English: Each 0.4 ml pipette contains: Active substances: 40 mg imidacloprid, 4 mg moxidectin
Estonian: Iga 0,4 ml pipett sisaldab : Toimeaine: 40 mg imidaklopriidi ja 4 mg moksidektiini.
English: EU/2/03/039/007 3 pipettes EU/2/03/039/008 6 pipettes EU/2/03/039/016 4 pipettes EU/2/03/039/025 21 pipettes EU/2/03/039/026 42 pipettes EU/2/03/039/043 1 pipette EU/2/03/039/044 2 pipettes EU/2/03/039/045 9 pipettes EU/2/03/039/046 12 pipettes
Estonian: EU/2/03/039/007 3 pipetti EU/2/03/039/008 6 pipetti EU/2/03/039/016 4 pipetti EU/2/03/039/025 21 pipetti EU/2/03/039/026 42 pipetti EU/2/03/039/043 1 pipett EU/2/03/039/044 2 pipetti EU/2/03/039/045 9 pipetti EU/2/03/039/046 12 pipetti
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Advocate for small dogs
Estonian: MINIMAALSED ANDMED, MIS PEAVAD OLEMA VÄIKESEL VAHETUL SISEPAKENDIL Advocate väikestele koertele
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Advocate for large dogs
Estonian: MINIMAALSED ANDMED, MIS PEAVAD OLEMA VÄIKESEL VAHETUL SISEPAKENDIL Advocate suurtele koertele
English: • the treatment of Eucoleus (syn.
Estonian: • Eucoleus (syn.
English: EU/2/03/039/005 3 pipettes EU/2/03/039/006 6 pipettes EU/2/03/039/015 4 pipettes EU/2/03/039/023 21 pipettes EU/2/03/039/024 42 pipettes EU/2/03/039/039 1 pipette EU/2/03/039/040 2 pipettes EU/2/03/039/041 9 pipettes EU/2/03/039/042 12 pipettes
Estonian: EU/2/03/039/005 3 pipetti EU/2/03/039/006 6 pipetti EU/2/03/039/015 4 pipetti EU/2/03/039/023 21 pipetti EU/2/03/039/024 42 pipetti EU/2/03/039/039 1 pipett EU/2/03/039/040 2 pipetti EU/2/03/039/041 9 pipetti EU/2/03/039/042 12 pipetti
English: EU/2/03/039/001 3 pipettes EU/2/03/039/002 6 pipettes EU/2/03/039/013 4 pipettes EU/2/03/039/019 21 pipettes EU/2/03/039/020 42 pipettes EU/2/03/039/031 1 pipette EU/2/03/039/032 2 pipettes EU/2/03/039/033 9 pipettes EU/2/03/039/034 12 pipettes
Estonian: EU/2/03/039/001 3 pipetti EU/2/03/039/002 6 pipetti EU/2/03/039/013 4 pipetti EU/2/03/039/019 21 pipetti EU/2/03/039/020 42 pipetti EU/2/03/039/031 1 pipett EU/2/03/039/032 2 pipetti EU/2/03/039/033 9 pipetti EU/2/03/039/034 12 pipetti
English: EU/2/03/039/003 3 pipettes EU/2/03/039/004 6 pipettes EU/2/03/039/014 4 pipettes EU/2/03/039/021 21 pipettes EU/2/03/039/022 42 pipettes EU/2/03/039/035 1 pipette EU/2/03/039/036 2 pipettes EU/2/03/039/037 9 pipettes EU/2/03/039/038 12 pipettes
Estonian: EU/2/03/039/003 3 pipetti EU/2/03/039/004 6 pipetti EU/2/03/039/014 4 pipetti EU/2/03/039/021 21 pipetti EU/2/03/039/022 42 pipetti EU/2/03/039/035 1 pipett EU/2/03/039/036 2 pipetti EU/2/03/039/037 9 pipetti EU/2/03/039/038 12 pipetti
English: The product was administered to ferrets at 5 times the recommended dose, every 2 weeks for 4 treatments, and there was no evidence of adverse effects or undesirable clinical signs.
Estonian: Preparaati manustati tuhkrutele soovituslikust doosist kuni 5 korda suuremas doosis igal 2. nädalal, 4 korda ning olulisi kõrvaltoimeid ei esinenud.
English: Roundworm, hookworm and whipworm treatment (Toxocara canis, Ancylostoma caninum, Uncinaria stenocephala, Toxascaris leonina and Trichuris vulpis).
Estonian: Solkmete, kidausside ja piugusside tõrje (Toxocara canis, Ancylostoma caninum, Uncinaria stenocephala, Toxascaris leonina ja Trichuris vulpis) Südameussidega ohustatud piirkonnas vähendab igakuine ravi märkimisväärselt ümarussidega taasnakatumise riski.
English: • the treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of Toxocara canis, Ancylostoma caninum and Uncinaria stenocephala, adults of
Estonian: • seedekulgla ümarusside (L4 vastsed, Toxocara canis ja Ancylostoma caninum ja
English: Weight of cat [kg]
Estonian: Kassi kaal [kg]
English: Do not use this veterinary medicinal product after the expiry date stated on the label and carton.
Estonian: Pärast sildil ja pakendil märgitud kõlblikkusaja lõppu seda veterinaarravimit mitte kasutada.
English: • the treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of Toxocara cati (roundworm) and Ancylostoma tubaeforme (hookworm).
Estonian: • seedekulgla ümarusside (L4 vastsed, Toxocara cati ja Ancylostoma tubaeforme täiskasvanud - ja noorvormid) nakkuse raviks.
English: Environmental properties
Estonian: Loomaliigid
English: The European Commission granted a marketing authorisation valid throughout the European Union for Provenge on 6 September 2013.
Estonian: Euroopa Komisjon andis Provenge müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 6. septembril 2013.
English: The leukapheresis and infusion are repeated on two further occasions, each approximately 2 weeks apart.
Estonian: Leukafereesi ja infusiooni korratakse veel kaks korda ligikaudu 2-nädalaste vahedega.
English: The patient should be monitored for at least half an hour after the infusion.
Estonian: Patsienti tuleb jälgida vähemalt pool tundi pärast infusiooni.
English: What measures are being taken to ensure the safe and effective use of Provenge?
Estonian: Mis meetmed võetakse, et tagada Provenge ohutu ja efektiivne kasutamine?
English: The full EPAR for Provenge can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Provenge kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: A risk management plan has been developed to ensure that Provenge is used as safely as possible.
Estonian: Töötati välja riskijuhtimisstrateegia, et tagada Provenge võimalikult ohutu kasutamine.
English: In a main study involving 512 patients, the average overall survival for patients treated with Provenge was 25.8 months, compared with 21.7 months for patients given placebo.
Estonian: Põhiuuringus, milles osales 512 patsienti, oli patsientide keskmine üldine elulemus Provenge rühmas 25,8 kuud ja platseeborühmas 21,7 kuud.
English: Other information about Provenge
Estonian: Muu teave Provenge kohta
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Provenge's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Provenge kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: It will also supply cards for patients to record the scheduled leukapheresis and infusion dates.
Estonian: Ettevõte annab patsientidele ka kaardid, kuhu märkida kavandatava leukafereesi ja infusiooni kuupäevad.
English: It must be given under the supervision of a doctor experienced in the treatment of prostate cancer and in an environment where resuscitation equipment is available.
Estonian: Seda peab manustama eesnäärmevähi ravis kogenud arsti järelevalve all ja keskkonnas, kus on olemas elustamisvahendid.
English: Why is Provenge approved?
Estonian: Miks Provenge heaks kiideti?
English: Further studies will also be carried out to provide additional supportive data on the effectiveness of Provenge.
Estonian: Korraldatakse ka edasisi uuringuid, et saada Provenge efektiivsuse kohta veel andmeid.
English: It is used when the cancer is metastatic (has spread to other parts of the body), and when medical or surgical castration (stopping the production of male hormones) has not worked or no longer works but treatment with chemotherapy (medicines that kill fast-growing cells like cancer cells) is not yet considered appropriate.
Estonian: Provenget kasutatakse, kui vähk on metastaatiline (levinud organismis mujale) ja kui meditsiiniline või kirurgiline kastreerimine (mis lõpetab meeshormoonide tekke) ei ole toiminud või ei toimi enam, kuid keemiaravi (ravi ravimitega, mis hävitavad kiirestikasvavaid rakke, näiteks vähirakke) ei peeta veel sobivaks.
English: Regarding its safety, the CHMP noted that Provenge was generally well tolerated.
Estonian: Ohutuse kohta märkis komitee, et Provenget taluti üldiselt hästi.
English: What is Provenge and what is it used for?
Estonian: Mis on Provenge ja milleks seda kasutatakse
English: The company will also set up an EUbased registry of patients treated with Provenge in order to monitor overall survival and side effects reported (particularly stroke and heart attack), and will provide data from a US-based registry.
Estonian: Samuti koostab ettevõte Provengega Euroopa Liidus ravitavate patsientide registri, et jälgida üldist elulemust ja teatatud kõrvalnähte (eriti insulti ja südameinfarkti), ning esitab andmed USA registrist.
English: This is a summary of the European public assessment report (EPAR) for Provenge.
Estonian: See on ravimi Provenge Euroopa avaliku hindamisaruande kokkuvõte.
English: Around half an hour before each infusion, the patient should take paracetamol and an antihistamine to reduce infusion-related reactions with Provenge.
Estonian: Pool tundi enne iga infusiooni peab patsient võtma Provenge infusiooniga seotud reaktsioonide vähendamiseks paratsetamooli ja antihistamiinikumi.
English: Provenge autologous peripheral blood mononuclear cells activated with PAP-GM-CSF (sipuleucel-T)
Estonian: Provenge autoloogsed PAP-GM-CSF-aktiveeritud perifeersed mononukleaarsed vererakud (sipuleukeel-T)
English: The main risks included acute infusion reactions, toxicities associated with the leukapheresis procedure and infections, but the CHMP considered that these were manageable and adequately addressed by risk minimisation measures for this medicine.
Estonian: Peamised riskid on muu hulgas ägedad infusioonireaktsioonid, leukafereesiga seotud toksilisus ja infektsioonid, kuid komitee leidis, et need on ravitavad ja ravimi riskivähendusmeetmed on piisavad.
English: Once prepared, the medicine is given as an infusion lasting around 1 hour.
Estonian: Valmis ravimit manustatakse ligikaudu 1 tund kestva infusioonina.
English: Serious side effects with Provenge include severe acute infusion reactions, severe infection (catheter sepsis and staphylococcal bacteraemia), heart attack and cerebrovascular events (related to the blood supply to the brain).
Estonian: Provenge rasked kõrvalnähud on muu hulgas rasked ägedad infusioonireaktsioonid, raske infektsioon (kateetrisepsis ja stafülokokiline baktereemia), südameinfarkt ja tserebrovaskulaarsed sündmused (seoses aju verevarustusega).
English: Three days before the infusion, a procedure called leukapheresis is performed to collect immune cells from the patient's blood, and these are then sent to a manufacturing facility to prepare the medicine.
Estonian: Kolm päeva enne infusiooni sooritatakse leukaferees ehk protseduur, millega kogutakse patsiendi verest immuunrakke, mis saadetakse ravimi tootmiskohta, kus valmistatakse nendest ravim.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Provenge, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Strateegiast lähtudes lisati ravimi omaduste kokkuvõttesse ja pakendi infolehele Provenge ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavate ettevaatusmeetmete teave.
English: Provenge is an immunotherapy, a medicine that stimulates the immune system to kill cancer cells.
Estonian: Provenge on immuunravim, mis stimuleerib immuunsüsteemi hävitama vähirakke.
English: When the immune cells are infused back into the patient, they stimulate an immune response against PAP, resulting in the immune system attacking and killing prostate cancer cells because they contain PAP.
Estonian: Kui immuunrakud viiakse infusiooniga tagasi patsiendi organismi, stimuleerivad need immuunvastust PAPi vastu, pannes immuunsüsteemi ründama ja hävitama eesnäärme vähirakke, sest need sisaldavad PAPi.
English: In addition, the company that markets Provenge will provide educational materials for doctors and patients on how to use the medicine and the leukapheresis procedure.
Estonian: Lisaks annab Provenget turustav ettevõte arstidele ja patsientidele ravimi kasutamise ja leukafereesi protseduuri teabematerjalid.
English: Provenge is a cancer medicine that is prepared specifically for each patient using their own immune cells (cells that form part of the body's natural defences).
Estonian: Provenge on vähiravim, mis valmistatakse spetsiaalselt igale patsiendile tema enda immuunrakkudest (immuunsüsteemi ehk organismi loodusliku kaitsemehhanismi rakkudest).
English: The CHMP concluded that the improvement in overall survival seen with Provenge is important for patients.
Estonian: Komitee järeldas, et Provenge korral täheldatud üldise elulemuse paranemine on patsientide jaoks tähtis.
English: The most common side effects with Provenge (which may affect more than 1 in 10 people) include chills, fatigue (tiredness), pyrexia (fever), nausea (feeling sick), arthralgia (joint pain), headache and vomiting.
Estonian: Provenge kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on külmavärinad, väsimus, palavik, iiveldus, liigesevalu, peavalu ja oksendamine.
English: Provenge is used to treat adult men with cancer of the prostate (a gland of the male reproductive system) who have few or no symptoms.
Estonian: Provenget kasutatakse eesnäärmevähiga (eesnääre on meeste reproduktiivsüsteemi nääre) täiskasvanud meeste raviks, kellel on sümptomeid vähe või puuduvad need üldse.
English: What are the risks associated with Provenge?
Estonian: Mis riskid Provengega kaasnevad?
English: It contains immune cells that are extracted from the patient's blood.
Estonian: Ravim sisaldab patsiendi verest eraldatud immuunrakke.
English: Provenge was shown to improve overall survival (the average length of time the patients lived) of patients with castration-resistant metastatic prostate cancer, compared with placebo (a dummy treatment).
Estonian: Uuringutes selgus, et Provenge parandab kastratsiooniresistentse metastaatilise eesnäärmevähiga patsientide üldist elulemust (keskmine aeg, kui kaua patsiendid elasid) võrreldes platseeboga (näiv ravim).
English: This type of prostate cancer is called castration-resistant matastatic prostate cancer.
Estonian: Sellist tüüpi eesnäärmevähki nimetatakse kastratsiooniresistentseks metastaatiliseks eesnäärmevähiks.
English: For the full list of all side effects reported with Provenge, see the package leaflet.
Estonian: Provenge kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: How is Provenge used?
Estonian: Kuidas Provenget kasutatakse?
English: For practical information about using Provenge, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Provenge kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: For more information about treatment with Provenge, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Provengega toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: It is not intended to provide practical advice on how to use Provenge.
Estonian: Hindamisaruandes ei anta Provenge kasutamise praktilisi nõuandeid.
English: Provenge is available as a liquid dispersion for infusion (drip) into a vein.
Estonian: Provenget turustatakse vedela infusioonidispersioonina (veeni tilgutatava dispersioonina).
English: What benefits of Provenge have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Provenge kasulikkus?
English: These cells are then mixed outside the patient's body with a ‘fusion protein', which is taken up by the cells.
Estonian: Rakud segatakse väljaspool patsiendi organismi liitvalguga, mille rakud omastavad.
English: Provenge is a type of advanced therapy medicine called a ‘somatic cell therapy product'.
Estonian: Provenge on somaatilise rakuteraapia ravimite hulka kuuluv uudne ravim.
English: Provenge can only be obtained with a prescription.
Estonian: Provenge on retseptiravim.
English: The fusion protein consists of prostatic acid phosphatase (PAP), a molecule found in most prostate cancer cells, attached to granulocyte-macrophage colony-stimulating factor (GM-CSF), a molecule that activates immune cells.
Estonian: Liitvalk koosneb eesnäärme happelisest fosfataasist (PAP), mis ainet sisaldub enamikus eesnäärme vähirakkudes.
English: How does Provenge work?
Estonian: Kuidas Provenge toimib?
English: A smaller supportive study was also carried out in adults and similar results were seen in this study.
Estonian: Väiksem toetav uuring viidi läbi ka täiskasvanutel ning selles uuringus täheldati sarnaseid tulemusi.
English: Young children are most at risk, followed by adolescents.
Estonian: Kõige suuremas ohus on väikelapsed ja seejärel noorukid.
English: Bexsero should be used according to official recommendations.
Estonian: Bexserot tuleb kasutada vastavalt ametlikele soovitustele.
English: Further information on Bexsero can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Lisateave Bexsero kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Bexsero?
Estonian: Mis meetmed võetakse, et tagada Bexsero ohutu ja efektiivne kasutamine?
English: The number of injections given, and the interval between them, varies depending on the age of the patient.
Estonian: Süstimiskordade arv ja nendevaheline ajavahemik sõltub patsiendi vanusest.
English: The second main study involved 1,631 adolescents aged between 11 and 17.
Estonian: Teises põhiuuringus osales 1631 noorukit vanuses 11 kuni 17 aastat.
English: Although group B meningococcal disease is relatively uncommon in Europe, it is more common in certain regions of Europe.
Estonian: Kuigi B-rühma bakterite põhjustatud meningokokkinfektsioon on Euroopas suhteliselt harv, on see mõnes Euroopa piirkonnas sagedam.
English: The European Medicines Agency decided that Bexsero's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Bexsero kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: Bexsero received a marketing authorisation valid throughout the EU on 14 January 2013.
Estonian: Bexsero müügiluba, mis kehtib kogu Euroopa Liidus, anti 14. jaanuaril 2013.
English: Other information about Bexsero
Estonian: Muu teave Bexsero kohta
English: As for all medicines, data on the use of Bexsero are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Bexsero kasutamise kohta pidevat järelevalvet.
English: What is Bexsero and what is it used for?
Estonian: Mis on Bexsero ja milleks seda kasutatakse?
English: The first main study involved 2,627 children who were two months old when the study started.
Estonian: Esimeses uuringus osales 2627 last, kes olid uuringu alguses 2-kuused.
English: For more information about using Bexsero, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Bexsero kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Side effects reported with Bexsero are carefully evaluated and any necessary action taken to protect patients.
Estonian: Bexsero kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Bexsero have been included in the summary of product characteristics and the package leaflet.
Estonian: Bexsero ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: What are the risks associated with Bexsero?
Estonian: Mis riskid Bexseroga kaasnevad?
English: Invasive disease occurs when the bacteria spread through the body causing serious infections such as meningitis (infection of the membranes that surround the brain and spine) and septicaemia (blood infection).
Estonian: Invasiivne haigus tekib, kui bakterid levivad kogu organismis, põhjustades raskeid infektsioone, nagu meningiit (pea- ja seljaaju ümbritsevate kelmete põletik e ajukelmepõletik) ja sepsis (veremürgitus).
English: When the person is then exposed to the bacterium, these antibodies together with other components of the immune system will be able to kill the bacteria and help protect against the disease.
Estonian: Kui inimene puutub hiljem bakteriga kokku, hävitavad antikehad ja muud immuunsüsteemi osad bakteri ning aitavad kaitsta organismi haiguse eest.